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Background: Newer biologic therapies for breast cancer such as trastuzumab (T) have been reported to increase risk of heart failure and 
cardiomyopathy (HF/CM) in clinical trials, especially in combination with anthracycline (A) chemotherapy. It is unclear how rapidly this new modality 
has disseminated into practice, or its association with long-term incidence of HF/CM.
Methods: Using Medicare data linked with SEER cancer registry data from 2000-2007, we identified women age 67-94 with stage I-III breast 
cancer and 3-year incidence of HF/CM, stratified by: A+T, A alone, T alone, other chemotherapy (O), or no adjuvant therapy (N). HF/CM events were 
identified from Medicare claims. Poisson regression was used to quantify risk of HF/CM from adjuvant therapy, adjusting for age, race, cancer 
characteristics and comorbidities.
Results: The sample included 45,530 older women (mean 76.2 yrs, standard deviation 6.2yrs). Among women who received adjuvant therapy, the 
proportion who received T increased 8-fold from 2.7% in 2000 to 22.6% in 2007 (p<.001). Unadjusted 3-year HF/CM incidence was higher for A+T 
(22.0%) and T (19.9%) compared with N (14.5%), while A had lower incidence (13.1%) (p<.001). In adjusted analyses A+T (relative risk [RR]=2.46, 
p<.001), T(RR=1.75, p<.001) and A alone(RR=1.14,p=.006 ) were associated with higher HF/CM risk.
Conclusion: Trastuzumab is increasingly used among older women undergoing adjuvant breast cancer therapy, and HF/CM is a common 
complication persisting up to 3 years.
 
